Sangamo completes $111M Fabry asset sale to PTC
SANGAMO THERAPEUTICS, INC.
Rhea-AI Filing Summary
SANGAMO THERAPEUTICS, INC. (SGMOQ) has completed a court‑supervised sale of all assets primarily related to its ST‑920 Fabry disease gene therapy program to PTC Therapeutics, Inc. The transaction, conducted during Sangamo’s Chapter 11 proceedings, closed on September 17, 2026.
Under the Asset Purchase Agreement, Sangamo receives $111,000,000 in cash at closing, plus up to an additional $100,000,000 in contingent milestone payments, and PTC assumes certain specified liabilities. Sangamo discloses that its common stock has been delisted from the Nasdaq Capital Market, now trades on the OTC Basic Market as “SGMOQ,” and that trading during the Chapter 11 case is highly speculative, with potential recoveries for shareholders uncertain.
Positive
- Sale of ST‑920 assets generates $111 million in immediate cash plus up to $100 million in potential milestone payments, providing liquidity during Chapter 11.
- Buyer PTC Therapeutics assumes certain specified liabilities, which may reduce Sangamo’s future obligations tied to the ST‑920 program.
Negative
- Sangamo is in an ongoing Chapter 11 bankruptcy case and is operating as a debtor‑in‑possession.
- The company’s common stock has been suspended and delisted from the Nasdaq Capital Market and now trades on the OTC Basic Market as “SGMOQ.”
- Sangamo cautions that trading in its common stock is highly speculative and that trading prices may bear little or no relationship to any eventual recovery for shareholders in the Chapter 11 case.
Filing Explained
The filing adds that Sangamo remains a debtor-in-possession under the Delaware bankruptcy court’s jurisdiction after the September 17 closing; completing the asset sale did not itself end the Chapter 11 case.
8-K Event Classification
3 items: 1.03, 2.01, 9.01
3 items
Item 1.03
Bankruptcy or Receivership
Business
The company or a significant subsidiary has filed for bankruptcy or entered receivership.
Item 2.01
Completion of Acquisition or Disposition of Assets
Financial
The company completed a significant acquisition or sale of business assets.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Cash consideration at closing: $111,000,000
Contingent milestone consideration: Up to $100,000,000
Chapter 11 petition date: June 23, 2026
+4 more
7 metrics
Cash consideration at closing
$111,000,000
Paid by PTC Therapeutics to Sangamo at closing of the ST‑920 asset sale on September 17, 2026
Contingent milestone consideration
Up to $100,000,000
Additional payments to Sangamo upon achievement of specified milestones under the ST‑920 Asset Purchase Agreement
Chapter 11 petition date
June 23, 2026
Date Sangamo filed its voluntary Chapter 11 bankruptcy case (Case No. 26-10989) in Delaware
Bid deadline
August 4, 2026, 5:00 p.m. Eastern Time
Deadline for bids under the court‑approved bidding procedures order
Auction date
August 10, 2026
Date of court‑supervised auction where PTC was selected as successful bidder for the ST‑920 assets
Sale Order date
September 2, 2026
Date the Bankruptcy Court entered the Sale Order authorizing the ST‑920 asset sale to PTC
Closing date of asset sale
September 17, 2026
Date Sangamo completed the sale of the ST‑920 assets to PTC
Key Terms
Chapter 11, debtor-in-possession, Sale Order, Asset Purchase Agreement, +2 more
6 terms
Chapter 11 regulatory
"filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code"
Chapter 11 is a U.S. bankruptcy process that lets a financially distressed company keep operating while it reorganizes its debts and business plan under court supervision. Think of it as a formal pause that allows the company to renegotiate payments, shed contracts or assets, and seek a path to profitability instead of being liquidated; investors watch it because it can change the value and priority of claims, equity dilution, or the likelihood of recovery.
debtor-in-possession regulatory
"continued to operate its business as a “debtor-in-possession” under the jurisdiction"
A debtor-in-possession is a company that has filed for bankruptcy protection but is allowed to keep operating and managing its assets while a court oversees the restructuring process. Investors pay attention because this status can help preserve business value and cash flow during reorganization, affect the priority of new loans and claims, and shape how much existing shareholders and creditors ultimately recover—like a shopkeeper allowed to stay open while reorganizing debts under court supervision.
Sale Order regulatory
"the Court entered a Sale Order authorizing the sale of the Purchased Assets"
Asset Purchase Agreement financial
"as contemplated by the Asset Purchase Agreement (the “PTC APA”)"
An asset purchase agreement is a legal contract in which a buyer agrees to buy specific assets and contracts of a business rather than buying the company’s stock or ownership. It matters to investors because it determines exactly what is being bought and what liabilities stay behind — like buying the furniture and equipment from a store but not the building or past debts — which affects the deal’s value, taxes and future risk exposure.
Assumed Liabilities financial
"plus the assumption of certain specified liabilities of the Company (the “Assumed Liabilities”)"
contingent consideration financial
"up to an additional $100,000,000 in contingent consideration payable upon the achievement"
Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What major transaction did SANGAMO THERAPEUTICS, INC (SGMOQ) announce?
Sangamo completed the sale of all assets primarily related to its ST‑920 Fabry disease gene therapy program to PTC Therapeutics, receiving $111 million in cash at closing, up to $100 million in contingent milestones, and PTC’s assumption of certain specified liabilities.
How does the ST-920 asset sale affect Sangamo’s Chapter 11 process?
The ST‑920 sale was conducted under a court‑approved bidding process in Sangamo’s Chapter 11 case. PTC was selected as the successful bidder at an auction, and the Court entered a Sale Order on September 2, 2026 authorizing the transaction, which closed on September 17, 2026.
What consideration does Sangamo receive from PTC in this transaction?
Sangamo receives $111,000,000 in cash at closing and may receive up to an additional $100,000,000 in contingent consideration if specified milestones are achieved. PTC also assumes certain specified liabilities related to the ST‑920 assets.
What is Sangamo’s current stock trading status and symbol?
Sangamo’s common stock has been suspended and delisted from the Nasdaq Capital Market and now trades on the OTC Basic Market under the symbol “SGMOQ.” The company states that trading during the Chapter 11 case is highly speculative.
Why does Sangamo warn investors about trading SGMOQ during Chapter 11?
Sangamo cautions that trading in its common stock during the Chapter 11 case is highly speculative and poses substantial risks, noting that trading prices may bear little or no relationship to the actual recovery, if any, by shareholders in the bankruptcy process.
When did Sangamo file for Chapter 11 bankruptcy protection?
Sangamo filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code on June 23, 2026 in the United States Bankruptcy Court for the District of Delaware, and continues to operate as a debtor‑in‑possession.
AI-generated analysis. How Rhea-AI works. Not financial advice.
